MDGL, WW and AKBA are among pre market gainers

seekingalpha

2024-03-15

Gainers: Geron (GERN) +71% wins FDA AdCom backing for blood cancer drug.
Cardlytics (CDLX) +48% Q4 earnings call release
Madrigal Pharmaceuticals (MDGL) +25% granted FDA approval for NASH therapy.
AtlasClear Holdings (ATCH) +16%.
Akebia Therapeutics (AKBA) +16%.
RLX Technology (RLX) +9%.
WW International (WW) +7%.
Spectral (MDAI) +7%.
Groupon (GRPN) +6%.
PowerFleet (PWFL) +6%.
Acacia Research (ACTG) +6%.

More on pre market gainers & stock

I Worry That WW International, Formerly Weight Watchers, May Not Survive
WW International, Inc. (WW) Q4 2023 Earnings Call Transcript
Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown
Biggest stock movers today: ADBE, GERN, and more
WW expects to beat previously given Q1 subscriber guidance

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2419197385"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2419197385\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2419197385?lang=zh_CN&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","is_english":true,"pubTime":"2024-03-15 20:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2419197385","market":"nz","top_or_hot":-1,"title":"MDGL, WW and AKBA are among pre market gainers","media":"seekingalpha","content":"<html><body><ul> <li> <strong>Gainers:</strong> Geron (GERN) <span>+71% </span>wins FDA AdCom backing for blood cancer drug. </li> <li>Cardlytics (CDLX) +48% Q4 earnings call release </li> <li>Madrigal Pharmaceuticals (MDGL) +25% granted FDA approval for NASH therapy. </li> <li><a href=\"https://laohu8.com/S/ATCH\">AtlasClear</a> Holdings (ATCH) <span>+16%</span>.</li> <li>Akebia Therapeutics (AKBA) <span>+16%</span>.</li> <li>RLX Technology (RLX<span>) </span><span>+9%</span><span>.</span> </li> <li>WW International (WW) <span>+7%</span>.</li> <li>Spectral (MDAI) <span>+7%</span>.</li> <li>Groupon (GRPN) <span>+6%</span>.</li> <li>PowerFleet (PWFL) <span>+6%</span>.</li> <li>Acacia Research (ACTG) <span>+6%</span>.</li> </ul> <div> <h2>More on pre market gainers &amp; stock</h2> <ul> <li>I Worry That WW International, Formerly Weight Watchers, May Not Survive</li> <li>WW International, Inc. (WW) Q4 2023 Earnings Call Transcript</li> <li>Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown</li> <li>Biggest stock movers today: ADBE, GERN, and more</li> <li>WW expects to beat previously given Q1 subscriber guidance</li> </ul> </div></body></html>","source":"seekingalpha_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MDGL, WW and AKBA are among pre market gainers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMDGL, WW and AKBA are among pre market gainers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-15 20:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4079881-mdgl-ww-and-akba-are-among-pre-market-gainers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gainers: Geron (GERN) +71% wins FDA AdCom backing for blood cancer drug.  Cardlytics (CDLX) +48% Q4 earnings call release  Madrigal Pharmaceuticals (MDGL) +25% granted FDA approval for NASH therapy.  ...</p>\n\n<a href=\"https://seekingalpha.com/news/4079881-mdgl-ww-and-akba-are-among-pre-market-gainers\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GRPN","symbol_name":"GroupOn","start_time":0,"source_url":"https://seekingalpha.com/news/4079881-mdgl-ww-and-akba-are-among-pre-market-gainers","article_id":"2419197385","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2419197385","pubTimestamp":1710504651,"columns":[],"sourceInfo":{"source_id":"seekingalpha_hot_news","name":"SeekingAlpha"},"weMediaInfo":null,"summary":"Gainers: Geron  +71% wins FDA AdCom backing for blood cancer drug.  Cardlytics  +48% Q4 earnings call release  Madrigal Pharmaceuticals  +25% granted FDA approval for NASH therapy.  AtlasClear Holdings  +16%. Akebia Therapeutics  +16%. RLX Technology  +9%.  WW International  +7%. Spectral  +7%. Groupon  +6%. PowerFleet  +6%. Acacia Research  +6%.   More on pre market gainers & stock  I Worry That WW International, Formerly Weight Watchers, May Not Survive WW International, Inc.  Q4 2023 Earnings Call Transcript Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Biggest stock movers today: ADBE, GERN, and more WW expects to beat previously given Q1 subscriber guidance","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"GRPN":"GroupOn","BK4192":"特殊消费者服务","BK4585":"ETF&股票定投概念","BK4157":"电子设备和仪器","MDAI":"Spectral AI Inc.","BK4139":"生物科技","BK4075":"烟草","BK4164":"特殊金融服务","BK4009":"广告","BK4220":"综合零售","BK4082":"医疗保健设备","WW":"慧俪轻体","AKBA":"Akebia Therapeutics, Inc.","RLX":"雾芯科技","BK4526":"热门中概股","BK4588":"碎股","BK4123":"调查和咨询服务","ACTG":"阿卡西亚","BK4122":"互联网与直销零售","BK4551":"寇图资本持仓","GERN":"杰龙","CDLX":"Cardlytics Inc.","BK4563":"昨日强势股","BK4127":"投资银行业与经纪业","ATCH":"AtlasClear","MDGL":"Madrigal Pharmaceuticals, Inc."},"translate_title":"MDGL、WW和AKBA均在盘前上涨之列","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACTG":1,"AKBA":1,"ATCH":1,"CDLX":1,"GERN":1,"GRPN":1,"MDAI":1,"MDGL":1,"PWFL":1,"RLX":1,"WW":1},"content_text":"Gainers: Geron (GERN) +71% wins FDA AdCom backing for blood cancer drug.  Cardlytics (CDLX) +48% Q4 earnings call release  Madrigal Pharmaceuticals (MDGL) +25% granted FDA approval for NASH therapy.  AtlasClear Holdings (ATCH) +16%. Akebia Therapeutics (AKBA) +16%. RLX Technology (RLX) +9%.  WW International (WW) +7%. Spectral (MDAI) +7%. Groupon (GRPN) +6%. PowerFleet (PWFL) +6%. Acacia Research (ACTG) +6%.   More on pre market gainers & stock  I Worry That WW International, Formerly Weight Watchers, May Not Survive WW International, Inc. (WW) Q4 2023 Earnings Call Transcript Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Biggest stock movers today: ADBE, GERN, and more WW expects to beat previously given Q1 subscriber guidance","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}